Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.
Gastrointestinal (GI) cancer continues to be a leading cause of cancer morbidity and mortality worldwide. Over the past decade the treatment options for patients with GI cancers have increased with the advent of newer combination chemotherapy regimes. Despite these clinical advances, new strategies are warranted in order to improve the efficacy as well as the safety. New molecular targets have provided novel opportunities in the treatment of GI cancer. One of the most advanced new approaches to date is the use of targeted inhibitors of the epidermal growth factor receptor (EGFR). In this review we describe the current status of therapeutic strategies based on EGFR inhibitors in the treatment of GI cancer.
Macarulla
Teresa
T
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Casado
Esther
E
Ramos
Francisco Javier
FJ
Valverde
Claudia
C
Tabernero
Josep
J
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006131:Growth Inhibitors / Q000008:administration & dosage*; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases